Serum uric acid level in patients with relapsing-remitting multiple sclerosis

Area of Science:

• Neurology
• Biochemistry
• Immunology

Background:

• Uric acid (UA) is a key hydrophilic antioxidant.
• UA is associated with multiple sclerosis (MS) pathogenesis and progression.
• Understanding UA levels in different MS phases is crucial.

Purpose of the Study:

• To evaluate serum UA levels in patients with relapsing-remitting MS (RRMS) during different disease phases.
• To compare RRMS patient UA levels with those of a healthy control group.
• To investigate the potential role of UA in MS disease activity.

Main Methods:

• A randomized case-control study design was employed.
• Serum UA levels were measured using quantitative enzyme-linked immunosorbent assay (ELISA).
• 130 RRMS patients (85 remitting, 45 relapsing) and 50 controls were analyzed.

Main Results:

• Mean serum UA was 6.41±3.18 mg/dL (remitting MS), 4.76±1.66 mg/dL (relapsing MS), and 6.33±2.94 mg/dL (controls).
• Significant differences observed between relapsing MS and remitting MS (p<0.001).
• Significant difference noted between relapsing MS and controls (p=0.002), but not between remitting MS and controls (p=0.87).

Conclusions:

• Serum UA levels differ significantly between relapsing and remitting phases of MS.
• Lower UA levels in relapsing MS suggest a potential role in disease activity.
• UA may play a protective role against MS disease exacerbation.